NCI-MATCH trial finds the combination of dabrafenib and trametinib effective
Treatment with dabrafenib and trametinib, a drug combination designed to target cancers that harbor certain BRAF gene mutations, was effective in a trial of 35 patients representing 17 distinct tumor types. The single-arm ...
Jun 3, 2019
0
0